Sitamaquine

DRUG3 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), GlaxoSmithKline

Conditions

HIV InfectionsLeishmaniasis, VisceralPneumonia, Pneumocystis Carinii

Phase 1

Escalating Multiple-Dose Safety and Tolerance of WR 6026 Hydrochloride in HIV-Infected Subjects

CompletedNCT00000740

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections, Pneumonia, Pneumocystis Carinii

End: 1993-09-30Target: 44Updated: 2021-11-04

Phase 2

A Study of WR 6026 in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in HIV-Infected Patients

CompletedNCT00000863

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections, Pneumonia, Pneumocystis Carinii

End: 1998-07-31Target: 45Updated: 2021-10-28

A Study Evaluating Sitamaquine Compared With Amphotericin B In The Treatment Of Visceral Leishmaniasis.

CompletedNCT00381394

GlaxoSmithKlineLeishmaniasis, Visceral

Start: 2006-08-04End: 2007-09-14Updated: 2017-09-18